



NEW

Hemocor HPH[®] 1400 IUS Hemoconcentrator ISO Twist Lock Style Endcaps

From the
World Leader in
Hemoconcentration

Benefits

- Polysulfone membrane offers excellent biocompatibility
- Proprietary fiber manufacturing process ensures consistent performance
- No-rinse fiber for convenient set up
- Meets the biocompatibility requirements of ISO 10993-4 selection of tests for interactions with blood
- Manufactured under U.S. Patent 5,762,798




Proven Therapeutic Effectiveness


Using the Hemocor HPH hemoconcentrator:

- Reduces the need for homologous blood and blood products by providing patients with their own concentrated whole blood.
- Maintains the desired hematocrit level for oxygen transport to tissues.
- Decreases the risk of post-operative bleeding through the retention of platelets and plasma coagulation proteins.
- Maintains oncotic pressure by retaining plasma proteins while quickly and gently removing excess plasma water.
- Minimizes the need for diuretic use, which may be contraindicated for some patients.

Hemocor HPH® 1400-IUS



The Hemocor HPH 1400 sets the mark for high performance hemoconcentrators. The high performance of the HPH 1400 may be needed during cases with long cross-clamp times or when large volumes of fluid have been administered.



- Chenoweth, D.E., Cooper, SW., Hugh, T.E., et al: Complement Activation during Cardiopulmonary Bypass: Evidence of Generation of C3a and C5a anaphylatoxins. *New Engl. J. Med.* 304:497-504, 1981.
- Kaplan, A.A. Toueg, S., Kennedy, T.L., Complement Kinetics during Continuous sArteriovenous Hemofiltration: Studies with a New Polysulfone Hemofilter. *Blood Purification* 6:27-36, 1988.
- In vitro test results with bovine blood, end-to-end pressure drop, inlet conditions: Hct = 25%, total protein = 5 g/dl, temp = 37°C, Qb = 200 ml/min, TMP = 200 mmHg.

Hemoconcentration: The Treatment of Choice

The use of hemoconcentrators during cardiac bypass surgery has continued to rise rapidly. Hemoconcentration has become the preferred method of controlling hemodilution during cardiopulmonary surgery by surgeons and perfusionists throughout the world. This process is also being performed to maintain higher hematocrit levels and to reduce the need for additional blood products during and after bypass.

The Hemocor HPH 1400-IUS

The convenience of the “no-rinse” hemoconcentrator allows insertion into the extracorporeal circuit at any time during surgery without the need to rinse the unit. The Hemocor HPH 1400-IUS hemoconcentrator is designed using glycerine-free polysulfone membrane. Minntech Hemocor membranes have exceptional biocompatibility through a broad range of medical device applications and meet the biocompatibility requirements of ISO 10993-4 selection of tests for interactions with blood. The superior blood compatibility is also well documented with clinical evidence.^{1,2} Minntech’s expertise and knowledge, accumulated from years of development, manufacturing, and clinical experience, is reflected in the quality and innovation of the Hemocor HPH 1400-IUS.

Hemocor HPH 1400-IUS Hemoconcentrator Specifications

Product	HPH 1400-IUS
Membrane Surface Area (M ²)	1.3
Membrane Material	Polysulfone
Prime Volume (ml)	100
Molecular Weight cut-off (Daltons)	65,000
Pressure Drop ³ (mmHg)	78
Maximum Transmembrane Pressure (mmHg)	500
Overall Unit Length (cm)	25.3
Internal Unit Diameter (cm)	3.6
Fiber Internal Diameter (microns)	200
Tubing Connections	
Blood [mm (inch)]	ISO
Filtrate [mm (inch)]	6.35 (1/4)

Ordering Information

Product	Description	Packaging
HEMOCOR HPH 1400-IUS	No-rinse 1.3 M ² Hemoconcentrator	12/Case
HEMOCOR HCH-1	Hemoconcentrator Holder	1/Case

Notes:

THE HPH-1400-IUS is provided with a sterile and non-pyrogenic fluid pathway in an unopened, undamaged package.